Qiagen NV Share Price Xetra
Equities
NL0000240000
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
05-21 | QIAGEN NV : Berenberg maintains a Buy rating | ZD |
05-15 | Qiagen's Updated Clinical Decision Support Platform Secures EU Certification | MT |
Sales 2024 * | 2.01B 1.85B 158B | Sales 2025 * | 2.14B 1.97B 168B | Capitalization | 9.99B 9.22B 785B |
---|---|---|---|---|---|
Net income 2024 * | 404M 373M 31.75B | Net income 2025 * | 450M 415M 35.36B | EV / Sales 2024 * | 5.13 x |
Net Debt 2024 * | 314M 290M 24.66B | Net cash position 2025 * | 193M 178M 15.17B | EV / Sales 2025 * | 4.58 x |
P/E ratio 2024 * |
24.7
x | P/E ratio 2025 * |
22.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.86% |
Latest transcript on Qiagen NV
Managers | Title | Age | Since |
---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 60 | 31/01/15 |
Metin Colpan
FOU | Founder | 69 | 28/04/96 |
Roland Sackers
DFI | Director of Finance/CFO | 56 | 31/12/98 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 31/05/11 | |
Metin Colpan
FOU | Founder | 69 | 28/04/96 |
Lawrence Rosen
CHM | Chairman | 66 | 25/06/13 |
1st Jan change | Capi. | |
---|---|---|
+60.58% | 55.07B | |
-1.97% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.66% | 26.28B | |
-21.28% | 18.93B | |
+6.65% | 13.03B | |
+27.95% | 12.26B | |
+26.25% | 12.21B |